Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Lincoff

Showing results (51-60 of 116) with videos related to

Pageof 12
Sort By:
Circulation|February 9, 1999
Rapid platelet-function assay: an automated and quantitative cartridge-based methodJ W Smith, S R Steinhubl, A M Lincoff, et al.
Journal of the American College of Cardiology|April 1, 1995
Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) GroupS G Ellis, M J Cowley, P L Whitlow, et al.
Catheterization and Cardiovascular Diagnosis|September 1, 1997
Quantitative evaluation of local drug delivery using the InfusaSleeve catheterM Gottsauner-Wolf, Y Jang, M S Penn, et al.
The American Journal of Cardiology|May 1, 1995
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study GroupA M Lincoff, E J Topol, R M Califf, et al.
Journal of the American College of Cardiology|March 15, 1993
Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control studyA M Lincoff, E J Topol, A T Chapekis, et al.
Heart (British Cardiac Society)|September 17, 2003
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trialsH S Gurm, D L Bhatt, A M Lincoff, et al.
The American Journal of Cardiology|April 27, 2000
The benefit of abciximab in percutaneous coronary revascularization is not device-specificD L Bhatt, A M Lincoff, R M Califf, et al.
American Heart Journal|October 28, 1999
Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experienceI C Gilchrist, L H Gardner, J B Muhlestein, et al.
Journal of the American College of Cardiology|July 1, 1997
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic ComplicationsA M Lincoff, R M Califf, K M Anderson, et al.
Coronary Artery Disease|July 1, 1994
Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study GroupS G Ellis, A M Lincoff, B S George, et al.
Pageof 12

Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Circulation|February 9, 1999
Rapid platelet-function assay: an automated and quantitative cartridge-based methodJ W Smith, S R Steinhubl, A M Lincoff, et al.
Journal of the American College of Cardiology|April 1, 1995
Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) GroupS G Ellis, M J Cowley, P L Whitlow, et al.
Catheterization and Cardiovascular Diagnosis|September 1, 1997
Quantitative evaluation of local drug delivery using the InfusaSleeve catheterM Gottsauner-Wolf, Y Jang, M S Penn, et al.
The American Journal of Cardiology|May 1, 1995
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study GroupA M Lincoff, E J Topol, R M Califf, et al.
Journal of the American College of Cardiology|March 15, 1993
Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control studyA M Lincoff, E J Topol, A T Chapekis, et al.
Heart (British Cardiac Society)|September 17, 2003
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trialsH S Gurm, D L Bhatt, A M Lincoff, et al.
The American Journal of Cardiology|April 27, 2000
The benefit of abciximab in percutaneous coronary revascularization is not device-specificD L Bhatt, A M Lincoff, R M Califf, et al.
American Heart Journal|October 28, 1999
Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experienceI C Gilchrist, L H Gardner, J B Muhlestein, et al.
Journal of the American College of Cardiology|July 1, 1997
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic ComplicationsA M Lincoff, R M Califf, K M Anderson, et al.
Coronary Artery Disease|July 1, 1994
Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study GroupS G Ellis, A M Lincoff, B S George, et al.
Pageof 12